CeloNova BioSciences Inc

Related Content

For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020
News | Stents
Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-inferiority for Thrombotic Events

October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology ...

Home October 22, 2020
arrow
News | Stents
CeloNova Completes Enrollment of First Randomized 14-Day DAPT Trial For a Stent

July 24, 2020 — CeloNova BioSciences Inc. announced it successfully completed enrollment of the COBRA REDUCE randomized ...

Home July 24, 2020
arrow
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents
FDA Approves COBRA REDUCE Trial Expansion

October 27, 2017 — CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of ...

Home October 27, 2017
arrow
CeloNova Cobra Pzf stent
Technology | Stents
FDA Clears Nano-coated Coronary Stent to Reduce DAPT

March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra PzF ...

Home March 02, 2017
arrow
CeloNova, COBRA REDUCE trial, first patient enrolled, Cobra PzF coronary stent
News | Stents
CeloNova Enrolls First Patient in COBRA REDUCE Trial

February 10, 2016 — CeloNova BioSciences Inc. announced this week that the first patient has been enrolled in its COBRA ...

Home February 10, 2016
arrow
CeloNova BioSciences, Cobra PzF coronary stent system, second randomized trial, COBRA-REDUCE
News | Stents
FDA OKs Second Randomized Trial for COBRA PzF Coronary Stent System

September 23, 2015 — CeloNova BioSciences Inc. announced that it has received conditional approval to start an ...

Home September 23, 2015
arrow
stents, Cobra, celonova
News
Study of the COBRA PzF Coronary Stent Shows 3% TLR Rate

November 25, 2014 — CeloNova BioSciences, Inc., announced that positive frst-in-man (FIM) clinical trial results found ...

Home November 25, 2014
arrow
News
De Novo Coronary Lesions May Benefit from New Stent Treatment, Study Shows

March 17, 2009 – Twelve-month data from the ATLANTA Trial shows that the CATANIA Coronary Stent System with NanoThin ...

Home March 17, 2009
arrow
News
CATANIA Coronary Artery Stent Makes Live Case Debut During the Sociedad Venezolana de Cardiologia Intervencionista

March 12, 2009 - CeloNova BioSciences Inc. said yesterday physicians performing a live stent implantation during the ...

Home March 12, 2009
arrow
News
Color-Coded Embolic with Polyzene-F Coating Gains FDA Clearance for Arteriovenous Malformations

January 26, 2009 - CeloNova BioSciences Inc. recently received FDA 510(k) marketing clearance for Embozene Color ...

Home January 25, 2009
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now